A prospective study of antimullerian hormone as a potential predictor of chemotherapy induced menopause

Not Applicable

Recruiting

• Conditions: Chemotherapy induced menopause; Cancer - Other cancer types; Reproductive Health and Childbirth - Menstruation and menopause; Cancer - Breast

• Registration Number: ACTRN12611000613909
• Lead Sponsor: Hilary Martin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-06-15
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

*Female planned for first line gonadotoxic chemotherapy defined as chemotherapy associated with >25% rates of ovarian failure. Examples of appropriate chemotherapy regimens includes: FAC, FEC, AC, AC-T, , FEC-D, TAC, TC, R-CHOP, ABVD and BEACOPP
* Cancer treated with curative intent
* Age 18-45
* Premenopausal defined as at least 2 menstrual cycles within 180 days of study enrolment or if recently ceased oral or implantable contraception gonadotropin levels within premenopausal range
* Able to provide informed consent

Exclusion Criteria

* planned for long term GNRH analogue post chemotherapy
* hysterectomy and/or bilateral oophorectomy prior to commencement of chemotherapy
* pregnant at time of enrolment

Study & Design

• Study Type: Observational
• Study Design: Not specified